Chemoprevention Trial of Celecoxib in Patients with Barrett's-associated Dysplasia.

New York Presbyterian Hospital is participating in a National Cancer Institute sponsored multicenter chemoprevention trial in patients with Barrett's dysplasia of the esophagus. Subjects with Barrett’s esophagus complicated by either low or high grade esophageal dysplasia will be treated with celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, or placebo. The duration of the study is a minimum of 12 months. Patients will undergo regular surveillance endoscopy with biopsies every 3 or 6 months depending on the grade of dysplasia. Extra biopsies for novel biomarker studies will be obtained at these scheduled visits. 

A major goal of this study is to determine whether a COX-2 inhibitor can impact on Barrett’s dysplasia.

Investigators at Presbyterian campus:

Charles J. Lightdale, M.D.    
Peter Green, M.D.          
Reuben Garcia-Carrasquillo, M.D.

Investigator at Cornell campus:
Andrew J. Dannenberg, M.D.

Eligibility Criteria

• Age 18 or older
• Established diagnosis of Barrett’s esophagus with low or high grade dysplasia
• Willing to be randomized to Celecoxib or placebo
• Willing to abstain from regular or long term use of steroids and NSAIDs except for baby aspirin.

If interested, please contact Kevin Bukowski, R.N. by Email (kb416@columbia.edu), telephone (212) 305-3224 or fax (212) 305-9913